This Research Topic embraced the most recent translational findings in RBP-mediated processes in cancer. As Editors, we had the pleasure of accepting for publication five original research articles and one review, which discussed RBPs’ role in post-transcriptional processes and their implications for tumor subtyping, response to treatment, and survival.
As highlighted by García-Cárdenas et al., the identification of tumorigenic RBPs could fulfil the need to discover accurate and sensitive therapeutic targets for specific tumor subtypes. The authors highlighted that distinct RBPs are involved in colon (COAD) and rectal (READ) carcinomas. By combining genomic, transcriptomic, proteomic, and interactions data from 488 COAD, 155 READ patients, and 102 cancer cell lines, they were able to assign oncogenic RBPs for each tumour subtype. In COAD, the authors identified NAT10, NOP56, RBM12 and FKBP1A while in READ, CSE1L, and EMG1 were pointed out as the ones with the strongest potential for clinical applications.